Targeted Therapy of Myelofibrosis
Background. Myelofibrosis (primary myelofibrosis, post-essential trombocythemia myelofibrosis, post-polycythemia myelofibrosis) is the most complex and pressing problem among all Ph-negative myeloproliferative diseases. The present article summarizes the author’s experience of using new Janus kinase...
Saved in:
| Main Authors: | OYu Vinogradova, VA Shuvaev, IS Martynkevich, MM Pankrashkina, MS Fominykh, EV Efremova, KYu Krutikova, LB Polushkina, NN Sharkunov, SV Voloshin, AV Chechetkin |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Practical Medicine Publishing House
2017-10-01
|
| Series: | Клиническая онкогематология |
| Subjects: | |
| Online Access: | http://bloodjournal.ru/wp-content/uploads/2017/10/6_1.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Possibilities of targeted therapy for myelofibrosis: Moscow experience
by: O. Yu. Vinogradova, et al.
Published: (2022-11-01) -
Clinical and hematological factors predicting the effectiveness of ruxolitinib in primary and secondary myelofibrosis. Results of a prospective single-center study
by: O. Yu. Vinogradova, et al.
Published: (2024-09-01) -
Combination therapy with ruxolitinib plus low-dose cytarabine or mercaptopurine in patients with blast-phase myelofibrosis
by: M. S. Fominykh, et al.
Published: (2016-08-01) -
Molecular markers as possible efficacy predictors of targeted therapy for myelofibrosis: single-center study
by: O. Yu. Vinogradova, et al.
Published: (2023-12-01) -
Melanoma during Ruxolitinib Treatment for Myelofibrosis
by: Lingzhi Zhong, et al.
Published: (2025-07-01)